COLUMBUS part 1–7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma
This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.
Authors
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
Institutions
- National Center for Tumor Diseases (DE)
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1080/14796694.2025.2536459
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Pfizer
- Array BioPharma